The purpose of the international Lung Cancer Congress is to provide major cooperative groups hailing from the United States, Europe, and Asia with updates on recent breakthroughs in lung cancer research. As in past years, the eleventh congress will address the study of lung cancer from different angles: biological, pathological, staging, personalized therapy and the ongoing research of Cooperative Groups. The conference will also cover current topics of interest, such as maintenance therapy and novel targeted agents.
Congress participants have the opportunity to meet internationally prominent opinion leaders and take part in debates and discussions on controversial topics. Additionally, the meeting will adopt an original approach by including panel discussions with case scenarios, multidisciplinary tumor boards, question-and-answer sessions and afternoon translational workshops focusing on future strategies in development for the treatment of lung cancer.
The recurring theme throughout the conference will be non–small-cell lung cancer (NSCLC). However, the congress reserves the right to address other areas of interest such as therapy for small-cell lung cancer (SCLC) and mesothelioma.
Mesothelioma is not considered a type of lung cancer because it does not develop in the tissue of the lungs. Still, it is a serious illness that deserves careful study, as mesothelioma information is scarce.
Malignant mesothelioma is a rare type of cancer affecting the lining of the chest and/or abdomen. Those with exposure to airborne asbestos particles are more likely to develop the mesothelioma disease. Mesothelioma chemotherapy is usually the most effective treatment, but it may be replaced and/or combined with surgery and radiation therapy.
The Eleventh Lung Cancer Congress is not only targeted to medical, surgical and radiation oncologists linked to lung cancer research, but also to nurse practitioners, nurses, physician assistants, pharmacists, researchers and other healthcare professionals interested in the treatment of lung cancer.
At the conclusion of the Congress, the participants will leave with a furthered understanding of the areas addressed, including:
Appropriate therapy for patients with lung cancer based on biomarker status and tumor characteristics.
Approaches to improve treatment outcomes with first and second-line therapies in advanced lung cancer.
New approaches to deliver radiation therapy in lung cancer.
Personalized therapeutic approaches for patients with mesothelioma.
Clinical data on new targeted agents in development for lung cancer.
Current research activity in lung cancer from national and regional Cooperative Groups.
The Eleventh Lung Cancer Congress will be held until Sunday, July 11, 2010 in Rancho Palos Verdes, California.
For additional information, please visit the 11th International Lung Cancer Congress Web page:
http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/510
To download the conference agenda, click on:
